Updated on 2024/04/18

写真a

 
FUJII Keiko
 
Organization
Okayama University Hospital Assistant Professor
Position
Assistant Professor
External link

Degree

  • 博士（博士） ( 2003.3   岡山大学 )

  • M.D., Ph. D. ( 2003.3   Okayama University )

Research Interests

  • 造血幹細胞移植

  • CAR-T細胞療法

  • 末梢血幹細胞採取

Research Areas

  • Life Science / Hematology and medical oncology

Education

  • Graduate School of Medicine , Dentistry and Pharmaceutical Sciences    

    1998.4 - 2003.3

    　 More details

  • Hamamatsu University School of Medicine    

    1989.4 - 1995.3

    　 More details

Professional Memberships

 

Papers

  • Evaluating the efficiency and safety of large-volume leukapheresis using the Spectra Optia continuous mononuclear cell collection protocol for peripheral blood stem cell collection from healthy donors: A retrospective study. Reviewed International journal

    Yuichi Sumii, Keiko Fujii, Takumi Kondo, Tomohiro Urata, Maiko Kimura, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda, Nobuharu Fujii

    Transfusion   2023.10

    　More details

    Authorship：Corresponding author   Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Large-volume leukapheresis (LVL) refers to processing of more than three volumes of blood in a single session for peripheral blood stem cell collection. Recently, continuous mononuclear cell collection (cMNC) protocol has been developed using the Spectra Optia system, which is a widely used apheresis device. LVL using the novel protocol has been investigated in patients. However, the efficiency and safety of LVL in healthy donors using this protocol has not been characterized. Therefore, this study aimed to evaluate the efficiency and tolerability of CD34+ collection of LVL with the cMNC protocol in healthy donors. STUDY DESIGN AND METHODS: We retrospectively collected data on LVL (>3 total blood volume) and normal-volume leukapheresis (NVL) performed in healthy donors between October 2019 and December 2021. All procedures were performed using the cMNC protocol. RESULTS: Although pre-apheresis CD34+ cell count was lesser in LVL (23.5 vs. 58.0/μL, p < .001), CD34+ collection efficiency was comparable between LVL and NVL (61.2% vs. 61.4%, p = .966). Platelet loss was significantly higher in LVL compared to NVL (38.0% vs. 29.4%, p < .001), with no correlation between attrition of platelet and processing blood volume. Moreover, the incidence of citrate toxicity during procedures was comparable between the two groups (31.6% vs. 21.4%, p = .322). All LVL procedures could be completed without any adverse events. CONCLUSION: Allogeneic LVL procedure using Spectra Optia cMNC protocol was well tolerated by the donors and resulted in efficient collection of CD34+ cells, which was comparable to that of NVL.

    DOI： 10.1111/trf.17563

    PubMed

    researchmap

  • Efficient granulocyte collection method using high concentrations of medium molecular weight hydroxyethyl starch Reviewed

    Takumi Kondo, Keiko Fujii, Nobuharu Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2023.6

    　More details

    Authorship：Corresponding author   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    DOI： 10.1111/trf.17450

    researchmap

  • Risk factors for <scp>CAR‐T</scp> cell manufacturing failure among <scp>DLBCL</scp> patients: A nationwide survey in Japan

    Tomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, Keiko Fujii, Tomoko Henzan, Kaoru Kahata, Rie Yamazaki, Wataru Takeda, Yoshihiro Umezawa, Kentaro Fukushima, Takashi Ashida, Minami Yamada‐Fujiwara, Ryo Hanajiri, Noboru Yonetani, Yuma Tada, Yuji Shimura, Hidekazu Nishikii, Norio Shiba, Naoya Mimura, Jun Ando, Takayuki Sato, Yasuhiro Nakashima, Junko Ikemoto, Keita Iwaki, Shin‐ichiro Fujiwara, Masaki Ri, Tokiko Nagamura‐Inoue, Ryuji Tanosaki, Yasuyuki Arai

    British Journal of Haematology   2023.4

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    DOI： 10.1111/bjh.18831

    researchmap

  • Red blood cell depletion in small‐volume bone marrow processing using manipulation with third‐party red blood cells: A comparison of the performance of the <scp>COBE</scp> spectra and the spectra Optia systems Reviewed International journal

    Yuichi Sumii, Nobuharu Fujii, Keiko Fujii, Takumi Kondo, Tomohiro Urata, Maiko Kimura, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   62 ( 9 )   1829 - 1838   2022.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    BACKGROUND: For pediatric recipients, red blood cells (RBCs) are added to bone marrow (BM) collections before low RBC volume BM processing using COBE Spectra (COBE) or Spectra Optia (Optia). However, the processing efficiency of this approach has not been evaluated. This study aimed to evaluate RBC depletion and nucleated cell subpopulation recovery rates in third-party RBC-manipulated BM products processed with the COBE or Optia. STUDY DESIGN AND METHODS: We retrospectively collected data on RBC depletion from low RBC volume BM with third-party RBCs (manipulated group) and on conventional large-volume, BM (unmanipulated group) processing performed between September 2010 and December 2021. All procedures were performed using COBE or Optia. RESULTS: The median residual RBC volume in the manipulated group was 9.5 ml in COBE and 2.5 ml in Optia (p = .01). The median total nucleated cell (TNC) and mononuclear cell (MNC) were comparable between the manipulated groups using each cell separator (TNC, 40.8 vs. 47.1%; MNC, 78.3 vs. 79.4%). The manipulation did not adversely affect TNC and MNC recoveries in either device. In addition, Optia achieved similar CD34+ cell recovery to that in large-BM-volume processing using the same device (147.5 vs. 184.5%, p = .112). During a follow-up period, neutrophil engraftment was achieved in all patients who received third-party RBC-manipulated grafts, and platelet engraftment was achieved in all cases, except one. CONCLUSION: The addition of third-party RBC to low RBC volume BM collections from or for pediatric patients does not have any negative impact on either RBC depletion or hematopoietic cell recovery during processing with the widely used cell separator.

    DOI： 10.1111/trf.17039

    PubMed

    researchmap

    Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/trf.17039

  • Successful neutrophil engraftment supported by granulocyte transfusion in adult allogeneic transplant patients with peri-transplant active infection International journal

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Maiko Kimura, Masayuki Matsuda, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    Transfusion and Apheresis Science   61 ( 6 )   103453 - 103453   2022.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    Active infection at the time of allogeneic hematopoietic stem cell transplantation (HSCT) is a risk for non-relapse mortality (NRM) after HSCT. Granulocyte transfusion (GTX) has been used to prevent or treat life-threatening infections in patients with severe neutropenia. However, data are limited on the clinical benefits of GTX during HSCT. We retrospectively analyzed the transplant outcomes of HSCT patients who had undergone GTX between 2012 and 2020. Altogether, 20 patients with documented infection had received 55 GTXs during HSCT. No adverse events were observed during the GTX infusion. The average number of granulocytes was 0.40 (range, 0.10-1.59) × 109/kg. The median neutrophil increment one day after GTX was 515 (range, -6 to 6630)/μl, which was significantly correlated with the infused granulocyte dose (p = 0.0007). A total of 17 of 20 patients achieved neutrophil engraftment. The number of infused granulocytes tended to higher in clinical responders (p = 0.12), and patients receiving ≥ 0.5 × 109/kg showed trend toward to better transplant outcomes (GTX-high vs. GTX-low, 1-year OS; 33% vs. 11%, p = 0.19. 1-year NRM; 44% vs.77%, p = 0.11). The type of red blood sedimenting agents was significantly correlated with the amounts of granulocyte collection. In conclusion, GTX, especially with a high amount of containing granulocytes, could be a safe bridging therapy for neutrophil engraftment after HSCT in patients with active infection.

    DOI： 10.1016/j.transci.2022.103453

    PubMed

    researchmap

  • Low hematocrit reduces the efficiency of <scp>CD34</scp> + cell collection when using the Spectra Optia continuous mononuclear cell collection procedure Reviewed

    Takumi Kondo, Nobuharu Fujii, Keiko Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Kana Washio, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken‐ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda

    Transfusion   2022.3

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Wiley  

    DOI： 10.1111/trf.16856

    researchmap

    Other Link： https://onlinelibrary.wiley.com/doi/full-xml/10.1111/trf.16856

  • Fatty layer separation and cell aggregation in channels during red cell depletion of bone marrow in stem cell transplantation Reviewed

    Keiko Fujii, Yuichi Sumii, Tomohiro Urata, Maiko Kimura, Takumi Kondo, Nobuharu Fujii

    Japanese Journal of Transfusion and Cell Therapy   68 ( 1 )   1 - 2   2022.2

    　More details

    Authorship：Lead author   Language：Japanese   Publishing type：Research paper (scientific journal)  

    researchmap

  • Effectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood progenitor cell collection Reviewed International journal

    Keiko Fujii, Nobuharu Fujii, Takumi Kondo, Toshiharu Mitsuhashi, Makoto Nakamura, Keisuke Seike, Yasuhisa Sando, Maiko Kimura, Masayuki Matsuda, Shuntaro Ikegawa, Hiroyuki Sugiura, Fumio Otsuka, Yoshinobu Maeda

    Transfusion and Apheresis Science   60 ( 4 )   103147 - 103147   2021.8

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)   Publisher：Elsevier BV  

    Peripheral blood progenitor cells (PBPCs) are a predominant graft source in allogeneic hematopoietic cell transplantation. Citrate-induced hypocalcemia remains the most frequent side effect of PBPC apheresis. Although the method for preventing severe adverse events is established, more efficient prophylaxis is required so that volunteer donors can donate PBPCs without pain and anxiety. We studied 80 healthy donors who underwent PBPC harvest between February 2014 and June 2020. Of these, 23 donors who underwent apheresis between February 2014 and December 2015 received only the standard prophylaxis of intravenous calcium gluconate. Oral calcium drinks were provided to 57 donors who underwent apheresis from January 2016 to June 2020 to supplement intravenous calcium gluconate prophylaxis. The ionized calcium (ICa) levels at multiple time intervals and the hypocalcemic symptoms were evaluated. Oral supplementation with a calcium drink maintained significantly higher ICa levels. Analysis using the inverse probability weighted regression adjustment method suggested that calcium drinks reduced the frequency of citrate-related reactions by 39.2 %. Administering a prophylactic oral calcium drink before apheresis with intravenous administration of calcium gluconate is promising to further reduce citrate-induced hypocalcemia in volunteer donors.

    DOI： 10.1016/j.transci.2021.103147

    PubMed

    researchmap

  • RETROSPECTIVE ANALYSIS OF PERIPHERAL BLOOD STEM CELL COLLECTION WITH Spectra Optia®, A NOVEL, AUTOMATIC INTERFACE-CONTROLLED APHERESIS SYSTEM: COMPARISON WITH COBE Spectra® Reviewed

    Fujii Keiko, Fujii Nobuharu, Asada Noboru, Nishimori Hisakazu, Kariyama Yuki, Ikeda Toru, Asano Naomi, Ogo Hiroaki, Iwatsuki Keiji

    Journal of the Japan Society of Blood Transfusion   59 ( 6 )   799 - 804   2013

    　More details

    Authorship：Lead author   Language：Japanese   Publisher：The Japan Society of Transfusion Medicine and Cell Therapy  

    G-CSF-mobilized peripheral blood stem cells (PBSCs) are frequently used for autologous and allogeneic hematopoietic cell transplantation. Although the COBE Spectra® Apheresis system has been commonly used, Spectra Optia®, a novel automatic interface-controlled apheresis system, became available at Okayama University Hospital in July 2011. We retrospectively analyzed a total of 73 cases of apheresis, 49 performed with the COBE system and 24 with the Optia system, for 51 autologous and 22 allogeneic PBSC samples collected between January 2011 and June 2012. For autologous PBSCs, total product volume and RBC contamination of products were significantly lower in the Optia group than in the Spectra group. For allogeneic PBSCs, total WBC counts and platelet contamination, as well as total product volume and RBC contamination, were lower in the Optia group than in the Spectra group, despite MNC collection efficacy and CD34+ cell numbers being similar in both groups for autologous and allogeneic PBSCs. Automatic apheresis with the Spectra Optia system is patient- and user-friendly, and has a similar collection efficacy to that of the COBE Spectra system.<br>

    DOI： 10.3925/jjtc.59.799

    CiNii Article

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2014217196

  • Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Reviewed

    FUJII K

    Br J Haematol   124 ( 2 )   190 - 194   2004.1

    　More details

    Authorship：Lead author   Language：English  

    CiNii Article

    researchmap

  • Over-expression of short isoforms of Helios in patients with adult T-cell leukaemia/lymphoma. Reviewed

    Over-expression of short, isoforms of Helios in, atients with adult T-cell leukaemia, lymphoma

    Br J Haematol   120 ( 6 )   986 - 989   2003.3

    　More details

    Authorship：Lead author   Language：English  

    DOI： 10.1046/j.1365-2141.2003.04216.x

    CiNii Article

    researchmap

  • Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.

    Kenta Hayashino, Keisuke Seike, Kanako Fujiwara, Kaho Kondo, Chisato Matsubara, Toshiki Terao, Wataru Kitamura, Chihiro Kamoi, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Daisuke Ennishi, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    International journal of hematology   119 ( 4 )   459 - 464   2024.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Although chimeric antigen receptor T-cell (CAR-T) therapies have dramatically improved the outcomes of relapsed/refractory B-cell malignancies, recipients suffer from severe humoral immunodeficiencies. Furthermore, patients with coronavirus disease 2019 (COVID-19) have a poor prognosis, as noted in several case reports of recipients who had COVID-19 before the infusion. We report the case of a 70-year-old woman who developed COVID-19 immediately before CAR-T therapy for high-grade B-cell lymphoma. She received Tixagevimab-Cilgavimab chemotherapy and radiation therapy but never achieved remission. She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term molnupiravir. On day 28 post-infection, lymphodepleting chemotherapy was restarted after a negative polymerase chain reaction (PCR) test was confirmed. The patient did not experience recurrence of COVID-19 symptoms or severe cytokine release syndrome. Based on the analysis and comparison of the previous reports with this case, we believe that CAR-T therapy should be postponed until a negative PCR test is confirmed. In addition, Tixagevimab-Cilgavimab and long term direct-acting antiviral agent treatment can be effective prophylaxis for severe COVID-19 and shortening the duration of infection.

    DOI： 10.1007/s12185-024-03711-5

    PubMed

    researchmap

  • Collection efficiency and safety of large-volume leukapheresis for the manufacturing of tisagenlecleucel. International journal

    Wataru Kitamura, Tomohiro Urata, Keiko Fujii, Takuya Fukumi, Kazuhiro Ikeuchi, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken-Ichi Matsuoka, Fumio Otsuka, Yoshinobu Maeda, Nobuharu Fujii

    Transfusion   2024.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: In patients with relapsed or refractory B cell acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma (r/r B-ALL/B-NHL) with low CD3+ cells in the peripheral blood (PB), sufficient CD3+ cell yield in a single day may not be obtained with normal-volume leukapheresis (NVL). Large-volume leukapheresis (LVL) refers to the processing of more than three times the total blood volume (TBV) in a single session for PB apheresis; however, the efficiency and safety of LVL for manufacturing of tisagenlecleucel (tisa-cel) remain unclear. This study aimed to investigate the tolerability of LVL. STUDY DESIGN AND METHODS: We retrospectively collected data on LVL (≥3-fold TBV) and NVL (<3-fold TBV) performed for patients with r/r B-ALL/B-NHL in our institution during November 2019 and September 2023. All procedures were performed using a continuous mononuclear cell collection (cMNC) protocol with the Spectra Optia. RESULTS: Although pre-apheresis CD3+ cells in the PB were significantly lower in LVL procedures (900 vs. 348/μL, p < .01), all patients could obtain sufficient CD3+ cell yield in a single day with a comparably successful rate of final products (including out-of-specification) between the two groups (97.2% vs. 100.0%, p = 1.00). The incidence and severity of citrate toxicity (no patients with grade ≥ 3) during procedures was not significantly different between the two groups (22.2% vs. 26.1%, p = .43) and no patient discontinued leukapheresis due to any complications. CONCLUSION: LVL procedures using Spectra Optia cMNC protocol was well tolerated and did not affect the manufacturing of tisa-cel.

    DOI： 10.1111/trf.17765

    PubMed

    researchmap

  • Clinical significance of gynecological examinations in long-term follow-ups

    Chihiro Kamoi, Nobuharu Fujii, Hirofumi Matsuoka, Kanayo Takahashi, Akira Yamamoto, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Japanese Journal of Transplantation and Cellular Therapy   13 ( 2 )   74 - 80   2024

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：The Japan Society for Hematopoietic Stem Cell Transplantation  

    DOI： 10.7889/tct-23-015

    researchmap

  • 再発・難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucel輸注後の早期再燃を予測する輸注前因子の検討

    北村 亘, 藤井 伸治, 鴨井 千尋, 浦田 知宏, 小林 宏紀, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本造血・免疫細胞療法学会雑誌   12 ( 4 )   259 - 267   2023.10

    　More details

    Language：Japanese   Publisher：(一社)日本造血・免疫細胞療法学会  

    researchmap

  • Distribution and clinical impact of molecular subtypes with Dark Zone signature of DLBCL in a Japanese real-world study. International journal

    Tomohiro Urata, Yusuke Naoi, Aixiang Jiang, Merrill Boyle, Kazutaka Sunami, Toshi Imai, Yuichiro Nawa, Yasushi Hiramatsu, Kazuhiko Yamamoto, Soichiro Fujii, Isao Yoshida, Tomofumi Yano, Ryota Chijimatsu, Hiroyuki Murakami, Kazuhiro Ikeuchi, Hiroki Kobayashi, Katsuma Tani, Hideki Ujiie, Hirofumi Inoue, Shuta Tomida, Akira Yamamoto, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Keisuke Sawada, Shuji Momose, Jun-Ichi Tamaru, Asami Nishikori, Yasuharu Sato, Tadashi Yoshino, Yoshinobu Maeda, David W Scott, Daisuke Ennishi

    Blood advances   2023.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The distribution and clinical impact of cell-of-origin (COO) subtypes of diffuse large B-cell lymphoma (DLBCL) outside Western countries remain unknown. Recent literature also suggests that there is an additional COO subtype associated with the germinal center dark zone, that warrants wider validation to generalize clinical relevance. Here, we assembled a cohort of Japanese patients with untreated DLBCL and determined the refined COO subtypes, that include the dark zone signature (DZsig), using the NanoString DLBCL90 assay. To compare the distribution and clinical characteristics of the molecular subtypes, we used a dataset from the cohort of BC Cancer (BCC) (n = 804). Of the 1050 patients where DLBCL90 assay was successfully performed in our cohort, 35%, 45%, and 6% of patients were identified to be germinal center B-cell-like (GCB)-DLBCL, activated B-cell-like (ABC)-DLBCL, and DZsigpos-DLBCL, respectively, with the highest prevalence of ABC-DLBCL differing significantly from that of BCC (P < 0.001). GCB-DLBCL, ABC-DLBCL, and DZsigpos-DLBCL were associated with two-year overall survival rates of 88%, 75%, and 66%, respectively (P < 0.0001), with patients of the DZsigpos-DLBCL having the poorest prognosis. In contrast, GCB-DLBCL without DZsig showed excellent outcomes following rituximab-containing immunochemotherapy. DZsigpos-DLBCL was associated with the significant enrichment of tumors with CD10 expression, concurrent MYC/BCL2 expression, and depletion of microenvironmental components (all P < 0.05). These results provide evidence of the distinct distribution of clinically relevant molecular subtypes in Japanese DLBCL and that refined COO, as measured by the DLBCL90 assay, is a robust prognostic biomarker that is consistent across geographical areas.

    DOI： 10.1182/bloodadvances.2023010402

    PubMed

    researchmap

  • Negative Prognostic Impact of High-Dose or Long-Term Corticosteroid Use in Patients with Relapsed or Refractory B-Cell Lymphoma Who Received Tisagenlecleucel. International journal

    Toshiki Terao, Wataru Kitamura, Nobuharu Fujii, Noboru Asada, Chihiro Kamoi, Kanako Fujiwara, Kaho Kondo, Chisato Matsubara, Kenta Hayashino, Keisuke Seike, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transplantation and cellular therapy   29 ( 9 )   573.e1-573.e8   2023.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The prognostic impact of corticosteroid therapy in patients receiving tisagenlecleucel (tisa-cel) treatment who are more likely to develop cytokine release syndrome (CRS) remains unclear. This study aimed to evaluate the clinical impact and lymphocyte kinetics of corticosteroid administration for CRS in 45 patients with relapsed and/or refractory B-cell lymphoma treated with tisa-cel. This was a retrospective evaluation of all consecutive patients diagnosed with relapsed and/or refractory diffuse large B-cell lymphoma, follicular lymphoma with histologic transformation to large B-cell lymphoma, or follicular lymphoma who received commercial-based tisa-cel treatment. The best overall response rate, complete response rate, median progression-free survival (PFS), and median overall survival (OS) were 72.7%, 45.5%, 6.6 months, and 15.3 months, respectively. CRS (predominantly grade 1/2) occurred in 40 patients (88.9%), and immune effector cell-associated neurotoxicity syndrome (ICANS) of all grades occurred in 3 patients (6.7%). No grade ≥3 ICANS occurred. Patients with high-dose (≥524 mg, methylprednisolone equivalent; n = 12) or long-term (≥8 days; n = 9) corticosteroid use had inferior PFS and OS to patients with low-dose or no corticosteroid use (both P < .05). The prognostic impact remained even in 23 patients with stable disease (SD) or progressive disease (PD) before tisa-cel infusion (P = .015). but not in patients with better disease status (P = .71). The timing of corticosteroid initiation did not have a prognostic impact. Multivariate analysis identified high-dose corticosteroid use and long-term corticosteroid use as independent prognostic factors for PFS and OS, respectively, after adjusting for elevated lactate dehydrogenase level before lymphodepletion chemotherapy and disease status (SD or PD). Lymphocyte kinetics analysis demonstrated that after methylprednisolone administration, the proportions of regulatory T cells (Tregs), CD4+ central memory T (TCM) cells, and natural killer (NK) cells were decreased, whereas the proportion of CD4+ effector memory T (TEM) cells was increased. Patients with a higher proportion of Tregs at day 7 had a lower incidence of CRS, but this did not affect prognosis, indicating that early elevation of Tregs may serve as a biomarker for CRS development. Furthermore, patients with higher numbers of CD4+ TCM cells and NK cells at various time points had significantly better PFS and OS, whereas the number of CD4+ TEM cells did not impact prognostic outcomes. This study suggests that high-dose or long-term corticosteroid use attenuates the efficacy of tisa-cel, especially in patients with SD or PD. Additionally, patients with high levels of CD4+ TCM cells and NK cells after tisa-cel infusion had longer PFS and OS.

    DOI： 10.1016/j.jtct.2023.06.018

    PubMed

    researchmap

  • 両側涙腺原発マントル細胞リンパ腫に対する末梢血幹細胞移植後10年診た1例

    松尾 俊彦, 田中 健大, 岡田 和也, 能登原 憲司, 藤井 敬子, 藤井 伸治

    日本リンパ網内系学会会誌   63   126 - 126   2023.6

    　More details

    Language：Japanese   Publisher：(一社)日本リンパ網内系学会  

    researchmap

  • 臍帯血移植後にHTLV-1感染T細胞の多クローン性増殖を伴って発症した肺合併症に対し抗CCR4抗体が著効した1例

    松原 千哲, 松岡 賢市, 近藤 歌穂, 藤原 加奈子, 寺尾 俊紀, 植田 裕子, 松村 彰文, 守山 喬史, 村上 裕之, 近藤 匠, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 藤井 伸治, 前田 嘉信

    臨床血液   64 ( 6 )   563 - 563   2023.6

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 臍帯血移植後にHTLV-1感染T細胞の多クローン性増殖を伴って発症した肺合併症に対し抗CCR4抗体が著効した1例

    松原 千哲, 松岡 賢市, 近藤 歌穂, 藤原 加奈子, 寺尾 俊紀, 植田 裕子, 松村 彰文, 守山 喬史, 村上 裕之, 近藤 匠, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 藤井 伸治, 前田 嘉信

    臨床血液   64 ( 6 )   563 - 563   2023.6

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 当院における再発難治性びまん性大細胞型B細胞性リンパ腫に対するtisagenlecleucelの治療成績

    北村 亘, 藤井 伸治, 鴨井 千尋, 阿部 将也, 住居 優一, 浦田 知宏, 谷 勝真, 高木 尚江, 山本 晃, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本輸血細胞治療学会誌   69 ( 2 )   331 - 331   2023.4

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • Bone marrow microenvironment disruption and sustained inflammation with prolonged haematologic toxicity after CAR T-cell therapy. International journal

    Wataru Kitamura, Noboru Asada, Yusuke Naoi, Masaya Abe, Hideaki Fujiwara, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    British journal of haematology   202 ( 2 )   294 - 307   2023.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Mechanisms of prolonged cytopenia (PC) after chimeric antigen receptor (CAR) T-cell therapy, an emerging therapy for relapsed or refractory diffuse large B-cell lymphoma, remain elusive. Haematopoiesis is tightly regulated by the bone marrow (BM) microenvironment, called the 'niche'. To investigate whether alterations in the BM niche cells are associated with PC, we analysed CD271+ stromal cells in BM biopsy specimens and the cytokine profiles of the BM and serum obtained before and on day 28 after CAR T-cell infusion. Imaging analyses of the BM biopsy specimens revealed that CD271+ niche cells were severely impaired after CAR T-cell infusion in patients with PC. Cytokine analyses after CAR T-cell infusion showed that CXC chemokine ligand 12 and stem cell factor, niche factors essential for haematopoietic recovery, were significantly decreased in the BM of patients with PC, suggesting reduced niche cell function. The levels of inflammation-related cytokines on day 28 after CAR T-cell infusion were consistently high in the BM of patients with PC. Thus, we demonstrate for the first time that BM niche disruption and sustained elevation of inflammation-related cytokines in the BM following CAR T-cell infusion are associated with subsequent PC.

    DOI： 10.1111/bjh.18747

    PubMed

    researchmap

  • Pre-infusion factors predicting early failure after tisagenlecleucel for patients with relapsed/refractory diffuse large B-cell lymphoma: A single institute retrospective analysis

    Wataru Kitamura, Nobuharu Fujii, Chihiro Kamoi, Tomohiro Urata, Hiroki Kobayashi, Akira Yamamoto, Keisuke Seike, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-ichi Matsuoka, Yoshinobu Maeda

    Japanese Journal of Transplantation and Cellular Therapy   12 ( 4 )   259 - 267   2023

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：The Japan Society for Hematopoietic Stem Cell Transplantation  

    DOI： 10.7889/tct-23-014

    researchmap

  • Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML. International journal

    Toshiki Terao, Ken-Ichi Matsuoka, Hiroko Ueda, Akifumi Matsumura, Chisato Matsubara, Kaho Kondo, Takumi Kondo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Blood advances   7 ( 5 )   681 - 686   2022.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1182/bloodadvances.2022008991

    PubMed

    researchmap

  • Association between early corticosteroid administration and long-term survival in non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation.

    Yui Kambara, Nobuharu Fujii, Yoshiaki Usui, Akira Yamamoto, Hisao Higo, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    International journal of hematology   117 ( 4 )   578 - 589   2022.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Non-infectious pulmonary complications (NIPCs) after allogeneic hematopoietic stem cell transplantation (HSCT) are associated with poor outcomes. It is important to maximize the effectiveness of primary treatment because secondary treatment has not been established. We analyzed data from 393 patients who underwent allogeneic HSCT during a 10-year period. Thirty-seven were diagnosed with NIPCs, which consisted of idiopathic pneumonia syndrome, bronchiolitis obliterans, and interstitial lung disease including cryptogenic organizing pneumonia. Among these, 18 died (Dead group) while 19 remained alive (Alive group) during the study period. The median time between NIPC diagnosis and first administration of ≥ 1 mg/kg/day corticosteroids (prednisolone dose equivalent) was significantly longer in the Dead group than the Alive group, at 9 days versus 4 days (p = 0.01). We further divided these cases into those who received prednisolone within seven days and after 8 days. We found that the ≤ 7 days group were more likely to survive after their NIPC diagnosis compared to the ≥ 8 days group (p = 0.06). Our analysis showed that early initiation of corticosteroid therapy is associated with long-term survival in NIPCs.

    DOI： 10.1007/s12185-022-03517-3

    PubMed

    researchmap

  • RAS/BRAF解析においてPCR-rSSO法とNGS法の併用による補完性が示された大腸癌の二例

    山本 英喜, 重安 邦俊, 柳井 広之, 井上 博文, 松岡 博美, 青江 伯規, 東影 明人, 藤井 敬子, 大塚 文男, 草野 展周, 平沢 晃

    日本臨床検査医学会誌   70 ( 補冊 )   258 - 258   2022.10

    　More details

    Language：Japanese   Publisher：(一社)日本臨床検査医学会  

    researchmap

  • RAS/BRAF解析においてPCR-rSSO法とNGS法の併用による補完性が示された大腸癌の二例

    山本 英喜, 重安 邦俊, 柳井 広之, 井上 博文, 松岡 博美, 青江 伯規, 東影 明人, 藤井 敬子, 大塚 文男, 草野 展周, 平沢 晃

    日本臨床検査医学会誌   70 ( 補冊 )   258 - 258   2022.10

    　More details

    Language：Japanese   Publisher：(一社)日本臨床検査医学会  

    researchmap

  • 岡山大学病院中央採血室の待ち状況のYouTubeライブ配信について

    東影 明人, 青江 伯規, 川下 隆二, 藤井 敬子, 山本 英喜, 大塚 文男

    日本臨床検査医学会誌   70 ( 補冊 )   166 - 166   2022.10

    　More details

    Language：Japanese   Publisher：(一社)日本臨床検査医学会  

    researchmap

  • Successful haematopoietic progenitor cell collection by plerixafor in combination with reduced dose granulocyte colony-stimulating factor for severe hypoxemia provoked by high-dose granulocyte colony-stimulating factor administration. International journal

    Yui Kambara, Noboru Asada, Kaori Kondo, Yuichi Sumii, Yuki Fujiwara, Keisuke Seike, Yasuhisa Sando, Kyosuke Saeki, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Transfusion medicine (Oxford, England)   2022.9

    　More details

    Language：English  

    DOI： 10.1111/tme.12916

    PubMed

    researchmap

  • Tisagenlecleucel投与後のステロイド抵抗性CRSに対し、cyclophosphamide投与を行い改善が得られた1例

    守山 喬史, 藤原 英晃, 村上 裕之, 松村 彰文, 大山 矩史, 淺田 騰, 西森 久和, 藤井 敬子, 藤井 伸治, 遠西 大輔, 末次 慶收, 松岡 賢市, 前田 嘉信

    臨床血液   63 ( 6 )   685 - 685   2022.6

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Tisagenlecleucel投与後のステロイド抵抗性CRSに対し、cyclophosphamide投与を行い改善が得られた1例

    守山 喬史, 藤原 英晃, 村上 裕之, 松村 彰文, 大山 矩史, 淺田 騰, 西森 久和, 藤井 敬子, 藤井 伸治, 遠西 大輔, 末次 慶收, 松岡 賢市, 前田 嘉信

    臨床血液   63 ( 6 )   685 - 685   2022.6

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Analysis of Immunity against Measles, Mumps, Rubella, and Varicella Zoster in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.

    Shohei Yoshida, Nobuharu Fujii, Chihiro Kamoi, Wataru Kitamura, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Acta medica Okayama   76 ( 3 )   247 - 253   2022.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Vaccine-preventable disease (VPD) infections are more severe in immunocompromised hosts. Vaccination against measles, mumps, rubella, and varicella zoster (VZV) (MMRV) is therefore recommended for hematopoietic stem cell transplantation (HCT) recipients. However, studies on adult HCT recipients with VPD infections are limited. At our institution, we have systematically conducted serological MMRV tests as a part of check-up examinations during long-term follow-up (LTFU) after HCT since 2015. This retrospective study aimed to evaluate changes in the serostatus between before and 2 years after allogeneic HCT. Among 161 patients, the pre-transplant seropositivity was 82.7% for measles, 86.8% for mumps, 84.2% for rubella, and 94.3% for VZV. Among 56 patients who underwent LTFU including serological MMRV tests at 2 years after HCT, the percentages maintaining seroprotective antibody levels for measles, mumps, rubella and VZV were 71.5% (40/56), 51.8% (29/56), 48.2% (27/56), and 60.7% (34/56), respectively. Vaccination was recommended for 22 patients, and 12 were vaccinated. Among the 12 vaccinated patients, rates of seroconversion were examined in 2-6 patients for each of the four viruses. They were 100% (3/3) for measles, 33.3% (1/3) for mumps, 50% (3/6) for rubella, and 0% (0/2) for VZV. Further studies are warranted to clarify the effect of vaccination in adult HCT recipients.

    DOI： 10.18926/AMO/63718

    PubMed

    researchmap

  • Chronic active Epstein–Barr virus infection presenting as refractory chronic sinusitis

    Wataru Kitamura, Hideaki Fujiwara, Akifumi Matsumura, Takaya Higaki, Rei Shibata, Tomohiro Toji, Soichiro Fujii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-ichi Matsuoka, Tadashi Yoshino, Yoshinobu Maeda

    International Journal of Hematology   2022.2

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s12185-022-03306-y

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s12185-022-03306-y/fulltext.html

  • Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group

    Wataru Kitamura, Nobuharu Fujii, Yuichiro Nawa, Keigo Fujishita, Hiroyuki Sugiura, Takanori Yoshioka, Yuki Fujiwara, Yoshiaki Usui, Keiko Fujii, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    International Journal of Hematology   115 ( 4 )   515 - 524   2022.2

    　More details

    Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1007/s12185-022-03290-3

    researchmap

    Other Link： https://link.springer.com/article/10.1007/s12185-022-03290-3/fulltext.html

  • Sequential Combination of FLAM and Venetoclax plus Azacitidine to Bridge to Cord Blood Transplantation in a Patient with Primary Induction Failure Acute Myeloid Leukemia. International journal

    Hiroyuki Murakami, Ken-Ichi Matsuoka, Takeru Asano, Takashi Moriyama, Akifumi Matsumura, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Tomohiro Toji, Tadashi Yoshino, Yoshinobu Maeda

    Case reports in oncology   15 ( 3 )   974 - 979   2022

    　More details

    Language：English  

    Venetoclax (VEN) is an oral B-cell lymphoma-2 (BCL-2) inhibitor that has been widely used to treat various hematological disorders. Recent studies have demonstrated that VEN in combination with fludarabine-enhanced high-dose cytarabine (FLA) is effective for treating relapsed or refractory acute myeloid leukemia (AML). In the combination therapy, salvage chemotherapy and VEN are basically concurrently administrated; however, further optimization may enable the treatment to apply to larger numbers of patients with various clinical backgrounds. Here, we describe a case of refractory AML treated with a sequential combination of the intensive chemotherapy (fludarabine, cytarabine, and mitoxantrone; FLAM) and VEN/AZA to bridge to an unrelated cord blood transplantation (uCBT). By continuously adding VEN/AZA after FLAM, the patient achieved morphologic leukemia free state with only minor toxicities. Blood cell counts did not recover until the time of transplantation because of the deep myelosuppression caused by the treatment sequence, but the infection risk was safely managed during this period. After engraftment, maintenance therapy with VEN/AZA was performed, and the patient has survived without disease recurrence for over 9 months after transplantation. Our case suggests that bridging therapy with VEN and AZA from the time of the last chemotherapy to allogeneic transplantation may provide an effective and tolerable treatment strategy for refractory AML. Further studies of larger numbers of cases are needed to validate the effectiveness of this treatment.

    DOI： 10.1159/000526697

    PubMed

    researchmap

  • Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype Presenting as Chorea During Treatment: A Case Report and Literature Review.

    Wataru Kitamura, Daisuke Ennishi, Ryoya Yukawa, Ryo Sasaki, Chikamasa Yoshida, Hiroki Takasuka, Hideaki Fujiwara, Noboru Asada, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Koji Abe, Tadashi Yoshino, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   60 ( 19 )   3155 - 3160   2021.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 72-year-old man presented with chorea while undergoing treatment for recurrence of nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype. An examination by brain N-isopropyl-p-iodoamphetamine (123I-IMP)-single photon emission computed tomography (SPECT) revealed no abnormalities other than a decreased cerebral blood flow (CBF) in the left striatum. After four courses of salvage chemotherapy, his clinical symptoms and asymmetric cerebral perfusion improved, suggesting that the decreased CBF had caused chorea. The significance of brain SPECT has not been fully clarified in patients with chorea-associated malignant lymphoma, warranting further investigations. Brain SPECT is an alternative approach to identify abnormalities in such patients.

    DOI： 10.2169/internalmedicine.7180-21

    PubMed

    researchmap

  • 移植後シクロホスファミドを用いた血縁者間HLA半合致移植後に最重症遅発性肝類洞閉塞症候群を合併した非定型慢性骨髄性白血病

    北村 亘, 藤井 伸治, 大西 秀樹, 高須賀 裕樹, 大山 矩史, 村上 裕之, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 木口 亨, 柳井 広之, 吉野 正, 前田 嘉信

    臨床血液   62 ( 6 )   654 - 655   2021.6

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 移植後シクロホスファミドを用いた血縁者間HLA半合致移植後に最重症遅発性肝類洞閉塞症候群を合併した非定型慢性骨髄性白血病

    北村 亘, 藤井 伸治, 大西 秀樹, 高須賀 裕樹, 大山 矩史, 村上 裕之, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 木口 亨, 柳井 広之, 吉野 正, 前田 嘉信

    臨床血液   62 ( 6 )   654 - 655   2021.6

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Effects of Gram-negative Rod Blood Stream Infection on Acute GVHD in Allogeneic Hematopoietic Stem Cell Transplantation: A Single-institute Analysis. Reviewed

    Masaaki Nishinohara, Hisakazu Nishimori, Hideaki Fujiwara, Noboru Asada, Daisuke Ennishi, Ken-Ichi Matsuoka, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    Acta medica Okayama   75 ( 3 )   279 - 287   2021.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A bloodstream infection (BSI) is the most common serious infectious complication of hematopoietic stem cell transplantation (HSCT). BSI promotes an inflammatory state, which exacerbates acute graft-versus-host disease (GVHD). We investigated whether a Gram-negative rod bloodstream infection (GNR-BSI), which develops early after allo-HSCT, affected the onset or exacerbated acute GVHD in 465 patients who underwent allo-HSCT from 1995 through 2015 at a single institution. Eighty-eight patients (19%) developed BSI during the study period. Among the cultures, 50 (57%) were Gram-positive cocci (GPC) and 31 (35%) were GNR. Of the 465 patients, 187 (40%) developed acute GVHD of grade II or higher within the first 100 days post-allogeneic HSCT: 124 (27%) had acute GVHD grade II, 47 (10%) had grade III, and 16 (3%) had grade IV. Multivariate analysis revealed that GNR-BSI was a significant risk factor for grade II-IV acute GVHD (grade II-IV: hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.03-2.97; grade III-IV: HR 2.37, 95% CI 1.03-5.43). These results suggest that GNR-BSI may predict the onset and exacerbation of acute GVHD.

    DOI： 10.18926/AMO/62219

    PubMed

    researchmap

  • 骨髄濃縮を行った骨髄移植72症例の後方視的検討 赤血球除去の有効性、骨髄凍結の安全性を含めて

    藤井 敬子, 木村 真衣子, 近藤 匠, 松田 真幸, 高橋 孝英, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 前田 嘉信, 大塚 文男, 藤井 伸治

    日本輸血細胞治療学会誌   67 ( 2 )   325 - 325   2021.5

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 長期的に赤血球輸血依存状態となった成人ドミナント型βサラセミア患者に対する根治治療としての造血幹細胞移植

    北村 亘, 藤井 伸治, 但馬 史人, 高須賀 裕樹, 大山 矩史, 村上 裕之, 木村 真衣子, 近藤 匠, 松田 真幸, 池川 俊太郎, 高木 尚江, 藤原 英晃, 淺田 騰, 遠西 大輔, 西森 久和, 藤井 敬子, 松岡 賢市, 前田 嘉信

    日本輸血細胞治療学会誌   67 ( 2 )   373 - 373   2021.5

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • Successful Treatment of Acute Promyelocytic Leukemia Complicated with Endometrial Cancer by Arsenic Trioxide.

    Hiroyuki Sugiura, Hisakazu Nishimori, Hirofumi Matsuoka, Keiichiro Nakamura, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Acta medica Okayama   75 ( 2 )   219 - 224   2021.4

    　More details

    Language：English  

    Acute promyelocytic leukemia (APL) is a hematological emergency that requires urgent intervention because of the high incidence of early hemorrhagic death. When patients with APL experience a synchronous solid organ tumor, the tumor's treatment must also be done properly. Differentiation-inducing therapy using arsenic trioxide (ATO) has less hematological toxicity compared to cytotoxic chemotherapy and might be preferable for untreated APL patients with a synchronous solid organ tumor. Here we describe the first successful case of untreated APL and synchronous endometrial cancer (in an adult Japanese woman) treated with ATO consolidation therapy and the subsequent surgery and chemotherapy for endometrial cancer.

    DOI： 10.18926/AMO/61904

    PubMed

    researchmap

  • Author Correction: 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. International journal

    Yasuhisa Sando, Ken-Ichi Matsuoka, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Hiroyuki Sugiura, Makoto Nakamura, Miki Iwamoto, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Atae Utsunomiya, Takashi Oka, Yoshinobu Maeda

    Scientific reports   11 ( 1 )   6420 - 6420   2021.3

    　More details

  • Pretransplant nivolumab further enhanced Treg expansion after posttransplant cyclophosphamide; another aspect for immune tolerance by PTCy after nivolumab. International journal

    Shuntaro Ikegawa, Yusuke Meguri, Kentaro Mizuhara, Takuya Fukumi, Hiroki Kobayashi, Yuichi Sumii, Takumi Kondo, Yasuhisa Sando, Miki Iwamoto, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yuka Fujisawa, Toshi Imai, Yoshinobu Maeda, Ken-Ichi Matsuoka

    Leukemia   35 ( 3 )   929 - 931   2021.3

    　More details

  • Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report. Reviewed International journal

    Masaya Abe, Nobuharu Fujii, Kentaro Mizuhara, Tomohiro Urata, Yuichi Sumii, Yuki Fujiwara, Keisuke Seike, Yasuhisa Sando, Makoto Nakamura, Keiko Fujii, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    Leukemia research reports   15   100241 - 100241   2021

    　More details

    Language：English  

    Owing to the poor prognosis of relapsed or refractory acute lymphoblastic leukemia (ALL), hematopoietic stem cell transplantation (HSCT) followed by effective salvage therapy is required. Inotuzumab ozogamicin (INO) was developed for ALL refractory to standard chemotherapy. However, previous reports suggest that sinusoidal obstruction syndrome (SOS) risk increases in patients with HSCT receiving INO, especially with dual alkylating agents. We report a case of relapsed Philadelphia chromosome-negative B-ALL where the patient underwent haploidentical HSCT using fludarabine/total body irradiation conditioning and posttransplant cyclophosphamide. Successful engraftment was achieved without SOS development.

    DOI： 10.1016/j.lrr.2021.100241

    PubMed

    researchmap

  • Allogeneic hematopoietic stem cell transplantation in a prior lung transplant recipient.

    Yuki Fujiwara, Ken-Ichi Matsuoka, Miki Iwamoto, Yuichi Sumii, Masaya Abe, Kentaro Mizuhara, Tomohiro Urata, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Junichi Sugita, Hajime Kobayashi, Takahiro Oto, Yoshinobu Maeda

    International journal of hematology   112 ( 6 )   871 - 877   2020.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Hematological diseases after solid organ transplant (SOT) are an emerging issue as the number of long-term SOT survivors increases. Expertise in managing patients requiring allogeneic hematopoietic stem cell transplantation (HSCT) after SOT from independent donors is needed; however, clinical reports of HSCT after SOT are limited, and the feasibility and risk are not well understood. In particular, HSCT in prior lung transplant recipients is thought to be complicated as the lung is immunologically distinct and is constantly exposed to the surrounding environment. Herein, we describe a case of successful HSCT in a patient with myelodysplastic syndromes who had previously received a lung transplant from a deceased donor for bronchiolitis obliterans syndrome. Reports about cases of HSCT after lung transplant are quite rare; thus, we discuss the mechanisms of immune tolerance through the clinical course of our case. This case suggests that HSCT after SOT can be considered a therapeutic option in cases where the transplanted organ is functionally retained and the hematological disease is in remission.

    DOI： 10.1007/s12185-020-02967-x

    PubMed

    researchmap

  • Post-transplantation cyclophosphamide restores early B-cell lymphogenesis that suppresses subsequent chronic graft-versus-host disease Reviewed International journal

    Miki Iwamoto, Shuntaro Ikegawa, Takumi Kondo, Yusuke Meguri, Makoto Nakamura, Yasuhisa Sando, Hiroyuki Sugiura, Yuichi Sumii, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Misako Shibakura, Yoshinobu Maeda, Ken-ichi Matsuoka

    Bone Marrow Transplantation   56 ( 4 )   956 - 959   2020.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    DOI： 10.1038/s41409-020-01100-0

    PubMed

    researchmap

    Other Link： http://www.nature.com/articles/s41409-020-01100-0

  • Persistent hypogammaglobulinemia due to immunoglobulin class switch impairment by peri-transplant rituximab therapy Reviewed

    Kentaro Mizuhara, Nobuharu Fujii, Yusuke Meguri, Takahide Takahashi, Michinori Aoe, Makoto Nakamura, Keisuke Seike, Yasuhisa Sando, Keiko Fujii, Masaya Abe, Yuichi Sumii, Tomohiro Urata, Yuki Fujiwara, Kyosuke Saeki, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    International Journal of Hematology   112 ( 3 )   422 - 426   2020.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    Post-transplant lymphoproliferative disorder (PTLD) is one of the most serious complications of allogeneic hematopoietic stem cell transplantation (HSCT). Rituximab is effective for PTLD; however, rituximab can produce adverse effects, including hypogammaglobulinemia. Here, we present the case of an 18-year-old female with refractory cytopenia of childhood who developed persistent selective hypogammaglobulinemia with low immunoglobulin G (IgG) 2 and IgG4 levels and monoclonal protein after rituximab therapy against probable PTLD. Despite B-cell recovery, the serum IgG levels gradually declined, reaching < 300 mg/dL at 33 months after rituximab treatment. In addition, class-switched memory (CD27 + IgD -) B cells were limited in phenotypic analysis. These findings suggest that peri-HSCT rituximab may contribute to an abnormal B-cell repertoire induced by impaired immunoglobulin class switch.

    DOI： 10.1007/s12185-020-02886-x

    PubMed

    researchmap

    Other Link： http://link.springer.com/article/10.1007/s12185-020-02886-x/fulltext.html

  • Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case. Reviewed

    Hiroyuki Sugiura, Hisakazu Nishimori, Kazuya Nishii, Tomohiro Toji, Keiko Fujii, Nobuharu Fujii, Ken-Ichi Matsuoka, Koh Nakata, Katsuyuki Kiura, Yoshinobu Maeda

    Internal medicine (Tokyo, Japan)   59 ( 16 )   2023 - 2028   2020.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Pulmonary alveolar proteinosis (PAP) is an uncommon lung disorder characterized by the excessive accumulation of surfactant-derived lipoproteins in the pulmonary alveoli and terminal bronchiole. Secondary PAP associated with primary myelofibrosis (PMF) is extremely rare, and to our knowledge, no autopsy case has been reported. We herein report an autopsy case of secondary PAP occurring in a patient with PMF who was treated with the Janus kinase 1/2 inhibitor ruxolitinib. We confirmed a diagnosis of PAP with complications based on the pathological findings at the autopsy. Notably, this case might suggest an association between ruxolitinib treatment and PAP occurrence.

    DOI： 10.2169/internalmedicine.4082-19

    PubMed

    researchmap

  • Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation

    Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

    TRANSFUSION   60 ( 3 )   473 - 478   2020.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：WILEY  

    BACKGROUND Cross-matched platelet (cross-matched PLT) transfusion is effective for immune-mediated platelet transfusion refractoriness (PTR), but is more costly and time-consuming for physical cross-match than using standard PLT units. Recent studies have reported the utility of human leucocyte antigens (HLA) virtual cross-matched PLT (HLA-matched PLT) that is defined as HLA-A/B matched or no antibody against donor-specific antigen. Here, we evaluated the effect of HLA-matched PLTs for PTR in post hematopoietic stem cell transplant (HSCT) recipients. STUDY DESIGN AND METHODS Our study included a total of 241 PLTs in 16 patients who underwent HSCT at Okayama University Hospital between 2010 and 2017, receiving either HLA-matched or cross-matched PLTs. We calculated the 24-hour corrected count increments (CCI-24) to evaluate the effect of PLTs. A CCI-24 >= 4500 was considered to be a successful transfusion. RESULTS We analyzed 139 cross-matched PLTs and 102 HLA-matched PLTs. In the immune-mediated PTR, the rate of successful transfusion was 60.5% for cross-matched PLT and 63.4% for HLA-matched PLT (p = 0.825). On the other hand, the median CCI-24 for cross-matched PLT transfusions and HLA-matched PLT transfusions were 1856 and 5824 (p < 0.001), with a success rate of 28.1 and 54.1% in cases with non-immune-mediated PTR, respectively (p = 0.001). CONCLUSION The effectiveness of HLA-matched PLT is not inferior to cross-matched PLT. This result indicates that physical cross-match can be omitted in post HSCT PTR.

    DOI： 10.1111/trf.15664

    Web of Science

    researchmap

  • 造血幹細胞運搬条件設定に関する取り組み

    浅野 尚美, 小郷 博昭, 池田 亮, 閘 結稀, 高木 尚江, 清家 圭介, 三道 康永, 中村 真, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   66 ( 1 )   78 - 78   2020.2

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 5-aminolevulinic acid-mediated photodynamic therapy can target aggressive adult T cell leukemia/lymphoma resistant to conventional chemotherapy. Reviewed

    Yasuhisa Sando, Ken-ichi Matsuoka, Yuichi Sumii, Takumi Kondo, Shuntaro Ikegawa, Hiroyuki Sugiura, Makoto Nakamura, Miki Iwamoto, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Atae Utsunomiya, Takashi Oka, Yoshinobu Maeda

    Scientific Reports   10 ( 1 )   17237   2020

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1038/s41598-020-74174-x.

    researchmap

  • CD34陽性細胞回収率の違いからみた処理血液量決定 末梢血幹細胞採取を効率よく終わらせるために

    藤井 敬子, 糸島 浩一, 岡田 健, 小川 弘子, 草野 展周, 大塚 文男

    臨床病理   67 ( 補冊 )   147 - 147   2019.10

    　More details

    Language：Japanese   Publisher：(一社)日本臨床検査医学会  

    researchmap

  • Macrophage elimination in bone marrow by dexamethasone palmitate is associated with successful engraftment in patients with hemophagocytic syndrome.

    Hiroyuki Sugiura, Ken-Ichi Matsuoka, Masayuki Matsuda, Shuntaro Ikegawa, Tomoko Inomata, Taiga Kuroi, Takeru Asano, Shohei Yoshida, Hisakazu Nishimori, Keiko Fujii, Nobuharu Fujii, Yoshinobu Maeda

    International journal of hematology   110 ( 2 )   260 - 262   2019.8

    　More details

  • 電子カルテシステムの既存機能を活用した骨髄像診断加算システムの構築と導入効果

    青江 伯規, 高橋 孝英, 川下 隆二, 日野 佳弥, 鳥越 佳子, 渡邊 夏希, 平畑 嵐紀, 岡田 健, 西森 久和, 藤井 敬子

    日本臨床検査自動化学会会誌   44 ( 4 )   523 - 523   2019.8

    　More details

    Language：Japanese   Publisher：(一社)日本医療検査科学会  

    researchmap

  • Plasma exchange eliminates residual mogamulizumab but does not warrant prompt recovery of peripheral Treg levels Reviewed International journal

    Sugiura H, Matsuoka KI, Sando Y, Meguri Y, Ikegawa S, Nakamura M, Iwamoto M, Yoshioka T, Asano T, Kondo E, Fujii K, Fujii N, Maeda Y

    Transfusion and Apheresis Science   58 ( 4 )   472 - 474   2019.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Mogamulizumab (Mog), a humanized anti-CCR4 antibody, provides an important treatment option for relapsed/refractory adult T cell leukemia/lymphoma. However, administration of Mog before allogenic hematopoietic stem cell transplantation has been reported to be a risk factor for severe acute graft-versus-host disease (GVHD). The etiological hypothesis is Mogamulizumab may eradicate CCR4-positive regulatory T cells (Tregs). Theoretically, Treg homeostasis and course of GVHD can be affected by plasma exchange (PE) with decreasing plasma Mog concentration. Here, we present a case of severe acute GVHD after pretransplantation Mog, in which PE was performed for liver failure. As a result, plasma Mog concentration was decreased but it did not lead to the prompt elevation of Treg levels in peripheral blood and clinical responses of GVHD were limited to partial remission. Our case suggests that recovery of donor-derived Treg in the acute phase after HSCT is multifactorial and the single procedure of PE-based Mog depletion does not necessarily warrant the quick restoration of Treg homeostasis.

    DOI： 10.1016/j.transci.2019.05.011

    PubMed

    researchmap

  • Cyclophosphamide(CY)が奏効した難治性TAFRO症候群の一例

    浦田 知宏, 遠西 大輔, 水原 健太郎, 阿部 将也, 住居 優一, 藤原 悠紀, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 西森 久和, 藤井 伸治, 藤井 敬子, 佐藤 康晴, 松岡 賢市, 吉野 正, 前田 嘉信

    日本リンパ網内系学会会誌   59   141 - 141   2019.5

    　More details

    Language：Japanese   Publisher：(一社)日本リンパ網内系学会  

    researchmap

  • 自家と同種におけるCD34陽性細胞回収率の違いからみた処理量決定 末梢血幹細胞採取を効率よく終わらせるために

    藤井 敬子, 藤井 伸治, 清家 圭介, 三道 康永, 中村 真, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 高木 尚江, 大塚 文男

    日本輸血細胞治療学会誌   65 ( 2 )   349 - 349   2019.4

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • Salvage Haploidentical Transplantation Using Low-dose ATG for Early Disease Relapse after First Allogeneic Transplantation: A Retrospective Single-center Review. Reviewed

    Okamoto S, Matsuoka KI, Sakamoto M, Usui Y, Fujiwara Y, Kondo T, Tani K, Saeki K, Meguri Y, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Maeda Y

    Acta medica Okayama   73 ( 2 )   161 - 171   2019.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse after first allo-SCT. Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportunity to conduct second SCT at the appropriate time, but the efficacy of second SCT from haploidentical donors after relapse has not been established. We retrospectively analyzed the records of 33 patients who underwent second SCT. Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 patients underwent conventional- SCTs, including HLA-matched related peripheral blood, unrelated bone marrow or cord blood. Three years after the second SCT, the overall survival (OS) and progression-free survival (PFS) of all patients were 32.5% and 23.9%. Multivariate analyses indicated that non-complete response at second SCT, less than 1-year interval to relapse after first- SCT, and total score ≥ 3 on the hematopoietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate. The haplo- and conventional- SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of relapse, non-relapse mortality and graft-versus-host disease. The neutropenic period after transplantation was significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.

    DOI： 10.18926/AMO/56652

    PubMed

    researchmap

  • Long-term outcomes in patients treated in the intensive care unit after hematopoietic stem cell transplantation.

    Makoto Nakamura, Nobuharu Fujii, Kazuyoshi Shimizu, Shuntaro Ikegawa, Keisuke Seike, Tomoko Inomata, Yasuhisa Sando, Keiko Fujii, Hisakazu Nishimori, Ken-Ichi Matsuoka, Hiroshi Morimatsu, Yoshinobu Maeda

    International journal of hematology   108 ( 6 )   622 - 629   2018.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    The number of patients who are successfully discharged from the intensive care unit (ICU) after hematopoietic stem cell transplantation (HSCT) remains limited. Most previous studies have evaluated short-term outcomes using ICU mortality; there have been comparatively fewer reports of long-term outcomes. We retrospectively analyzed 39 HSCT patients admitted to the ICU for the first time between April 2008 and July 2014. Performance status was evaluated in four long-term survivors in July 2016. Median age at ICU admission was 54 years (range 30-68). In total, 33 patients (70.2%) required mechanical ventilation and 31 patients (66%) required dialysis. The median OS from first ICU admission was 41 days (95% confidence interval [CI]: 22-64) and the 1-year survival rate was 12.8% (95% CI 4.7-25.2). No statistically significant factors were associated with short-term outcomes. Among long-term outcomes, a second or subsequent HSCT and neutropenia at ICU admission were significant risk factors. Four of 10 ICU survivors have survived with good performance status for a median of 1994 (1203-2633) days. Our results suggest that the number of prior transplants and neutropenia at ICU admission may influence OS.

    DOI： 10.1007/s12185-018-2536-x

    PubMed

    researchmap

  • 同種造血幹細胞移植後の好中球減少患者に対する顆粒球輸注療法

    藤井 伸治, 池川 俊太郎, 藤井 敬子, 佐伯 恭昌, 廻 勇輔, 浅田 騰, 西森 久和, 松岡 賢市, 大塚 文男, 前田 嘉信

    日本輸血細胞治療学会誌   64 ( 2 )   453 - 453   2018.4

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 自己血輸血の変遷 貯血式・希釈式・回収式症例数と時代背景を顧みて

    藤井 敬子, 高木 尚江, 清家 圭介, 三道 康永, 中村 真, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   64 ( 2 )   442 - 442   2018.4

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 健常人ドナーにおけるクエン酸中毒 CMNCモードとMNCモードで違いがあるのか

    藤井 敬子, 清家 圭介, 三道 康永, 中村 真, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   63 ( 6 )   823 - 823   2017.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 赤血球プライム下の骨髄濃縮 小児科、低体重児における骨髄処理

    藤井 敬子, 中村 真, 谷 勝真, 佐伯 恭昌, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 今田 昌秀, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   63 ( 3 )   424 - 424   2017.6

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • Predictors of vasovagal reactions during preoperative autologous blood donation: a single-institution analysis.

    Hisakazu Nishimori, Nobuharu Fujii, Keiko Fujii, Tohru Ikeda, Naomi Asano, Hiroaki Ogo, Miwa Yamakawa, Naoe Takagi, Fumio Otsuka, Kazuma Ikeda

    International journal of hematology   105 ( 6 )   812 - 818   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Studies examining risk factors associated with vasovagal reactions (VVRs) during autologous blood donations, especially in younger subjects, have been limited. The aim of the present study was to define risk factors for VVRs during preoperative autologous blood donation in patients, including those younger than 18 years old. We retrospectively analyzed 4192 autologous, preoperative blood donations between 2007 and 2015 at Okayama University Hospital. Eighty-seven (2.08%) of the patients experienced VVRs. VVRs occurred approximately three times as often in patients 0-17 years old (16/320, 5.0%) than in patients 18 years and older (71/3872, 1.8%). In particular, VVRs occurred more frequently in those 10-13 years old, and decreased with older age (P = 0.006). In a univariate analysis, younger age, lower body mass index, lower systolic blood pressure, lower body weight, lower total blood volume, female gender, first-time collection, and higher heart rate were associated with a higher incidence of VVRs. In a multivariate analysis, lower systolic blood pressure (P < 0.001), higher heart rate (P = 0.007), and first-time collection (P = 0.015), remained independent predictors of VVRs. These results emphasize the need for careful attention during blood collection.

    DOI： 10.1007/s12185-017-2204-6

    PubMed

    researchmap

  • Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. International journal

    Tatsunori Ishikawa, Nobuharu Fujii, Masahide Imada, Michinori Aoe, Yusuke Meguri, Tomoko Inomata, Hiromi Nakashima, Keiko Fujii, Shohei Yoshida, Hisakazu Nishimori, Ken-Ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Mitsune Tanimoto

    Cytotherapy   19 ( 4 )   514 - 520   2017.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND: Azacitidine (Aza) and donor lymphocyte infusion (DLI) therapy has recently been reported as an effective salvage therapy for relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Despite the high response rate and relatively long period of remission, most patients relapse again. The immunologic mechanism of the response and limited efficacy remain unknown. CASE REPORT: Aza + DLI therapy was performed for a patient with therapy-related MDS (t-MDS), who had relapsed after allogeneic peripheral blood stem cell transplantation. We observed a powerful graft-versus-leukemia (GVL) effect accompanied by an evident Wilms tumor antigen 1 (WT1)-specific CD8 T-cell response. Remission continued for 15 months, but finally the patient relapsed. The kinetics of the WT1-specific CD8 T cells were inversely associated with WT1 messenger RNA (mRNA), suggesting a WT1-driven GVL effect. DISCUSSION: A difference of T-cell phenotype between the whole T cells and the WT1-specific CD8 T cells was observed. It is of note that the memory phenotype of the WT1-specific T cell was limited and decreased early. The immunoescape mechanism was partly supported by loss of the memory phenotype due to failure of expansion and differentiation. CONCLUSION: Our data suggested that a WT1-specific T-cell response at least partly contributes to the GVL effect induced by Aza + DLI. A strategy for maximizing and maintaining the memory phenotype of the CTL may be required for durable remission.

    DOI： 10.1016/j.jcyt.2016.12.007

    PubMed

    researchmap

  • Spectra Optiaを用いた骨髄濃縮 小児科、低体重児における骨髄処理

    藤井 敬子, 中村 真, 谷 勝真, 佐伯 恭昌, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 今田 昌秀, 高木 尚江, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   62 ( 6 )   754 - 754   2016.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 末梢血幹細胞採取時の健常人ドナーにおけるクエン酸中毒発現、電解質異常についての解析

    藤井 敬子, 石川 立則, 吉岡 尚徳, 廻 勇輔, 藤原 英晃, 小林 優人, 高木 尚江, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   61 ( 6 )   593 - 593   2015.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • Complete resolution of steroid-resistant organizing pneumonia associated with myelodysplastic syndrome following allogeneic hematopoietic cell transplantation. International journal

    Takeru Asano, Nobuharu Fujii, Daigo Niiya, Hisakazu Nishimori, Keiko Fujii, Ken-Ichi Matsuoka, Koichi Ichimura, Toshihisa Hamada, Eisei Kondo, Yoshinobu Maeda, Yasushi Tanimoto, Katsuji Shinagawa, Mitsune Tanimoto

    SpringerPlus   3   3 - 3   2014

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Pulmonary complications in patients with hematological malignancies are often caused by infection but are sometimes associated with an underlying disease such as organizing pneumonia (OP). Here, we report a case of life-threatening steroid-resistant OP associated with myelodysplastic syndrome (MDS) and successfully performed allogeneic hematopoietic cell transplantation (HSCT). A 33-year-old female with refractory anemia with excess blasts-1 that had progressed from refractory anemia with ringed sideroblasts and concomitant Sweet's syndrome was admitted. Multiple pulmonary infiltrates were revealed on a chest computed tomography scan, which progressively worsened even after chemotherapy and corticosteroid therapy. No evidence of infection was observed in bronchoalveolar lavage fluid. A histological examination of a transbronchial lung biopsy specimen showed lymphocyte invasion with fibrosis, indicating that the pulmonary infiltrates were OP associated with MDS. Before transplantation, she suffered from respiratory failure and required oxygen supplementation. She developed idiopathic pneumonitis syndrome on day 61 that responded well to corticosteroid therapy, and the OP pulmonary infiltrates improved gradually after HSCT, She was discharged on day 104 and is well without recurrence of OP or MDS 2 years after HSCT.

    DOI： 10.1186/2193-1801-3-3

    PubMed

    researchmap

  • 健常人ドナー末梢血幹細胞採取時における副作用、電解質異常について

    藤井 敬子, 淺田 騰, 藤原 英晃, 山川 美和, 熊本 貴子, 狩山 由貴, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 岩月 啓氏

    日本輸血細胞治療学会誌   59 ( 6 )   865 - 865   2013.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 新しい全自動型血液成分分離装置Spectra Optiaを用いた末梢血幹細胞採取Cobe Spectraと比較して

    藤井 敬子, 淺田 騰, 西森 久和, 山川 美和, 森 繰代, 狩山 由貴, 池田 亮, 浅野 尚美, 小郷 博昭, 藤井 伸治, 岩月 啓氏

    日本輸血細胞治療学会誌   59 ( 1 )   91 - 91   2013.2

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 日本輸血・細胞治療学会による細胞療法の体制に関する全国調査

    藤井 敬子, 西森 久和, 藤井 伸治, 池田 亮, 浅野 尚美, 小郷 博昭, 岩月 啓氏, 池田 和眞, 田中 朝志, 佐川 公矯, 大戸 斉, 高橋 孝喜

    日本輸血細胞治療学会誌   57 ( 6 )   511 - 512   2011.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 輸血検査の検体間違いに関するインシデントの検討

    浅野 尚美, 池田 亮, 小郷 博昭, 山口 麻由美, 西森 久和, 藤井 敬子, 藤井 伸治, 池田 和眞, 岩月 啓氏

    日本輸血細胞治療学会誌   57 ( 6 )   507 - 507   2011.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 輸血に関するインシデントの検討

    浅野 尚美, 池田 亮, 小郷 博昭, 西森 久和, 藤井 敬子, 池田 和真, 小出 典男

    日本輸血細胞治療学会誌   57 ( 2 )   264 - 264   2011.3

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 同種末梢血幹細胞採取における至適タイミングの検討

    藤井 敬子, 池田 亮, 浅野 尚美, 小郷 博昭, 西森 久和, 小出 典男, 池田 和真

    日本輸血細胞治療学会誌   57 ( 2 )   281 - 281   2011.3

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 貯血式自己血採血における血管迷走神経反射の検討

    西森 久和, 藤井 敬子, 遠藤 麻里子, 池田 亮, 浅野 尚美, 小郷 博昭, 池田 和真, 小出 典男

    日本輸血細胞治療学会誌   57 ( 2 )   242 - 242   2011.3

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 当院での緊急時O型赤血球輸血の現状

    小郷 博昭, 池田 亮, 浅野 尚美, 遠藤 麻里子, 西森 久和, 藤井 敬子, 池田 和真, 小出 典男

    日本輸血細胞治療学会誌   57 ( 1 )   66 - 66   2011.2

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 当院での貯血式自己血採血における血管迷走神経反射の検討

    西森 久和, 藤井 敬子, 遠藤 麻里子, 池田 亮, 浅野 尚美, 小郷 博昭, 池田 和眞, 小出 典男

    日本輸血細胞治療学会誌   57 ( 1 )   64 - 64   2011.2

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • TRANSFUSION IN LUNG TRANSPLANTATION AT OKAYAMA UNIVERSITY HOSPITAL

    ASANO Naomi, IKEDA Toru, OGO Hiroaki, FUJII Keiko, SUGIYAMA Haruko, IKEDA Kazuma, KOIDE Norio

    Journal of the Japan Society of Blood Transfusion   56 ( 5 )   606 - 611   2010.10

    　More details

    Language：Japanese   Publisher：The Japan Society of Transfusion Medicine and Cell Therapy  

    As of March 2009, 67 lung transplants, including 52 from living donors and 15 from cadaveric donors, have been carried out since the first lung transplantation in Japan in 1998 at Okayama University Hospital. We analyzed the preparation and actual usage of blood products in lung transplantation during this period.<br> The average number of units of prepared and transfused red cells were 57.4 and 33.5, respectively, with a C/T ratio of 1.73. Average number of units of prepared and transfused fresh frozen plasma were 43.3 and 19.4, and those of platelet concentrate were 27.7 and 19.8, respectively. In double- and single-lung transplantation, the average number of units of transfused red cells, fresh frozen plasma and platelet concentrate were 37.9 and 11.5 (p<0.05), 21.8 and 7.0 (p<0.05), and 22.8 and 4.5 (p<0.05), respectively. In 5 double-lung transplants, more than 100 units of red blood cells were prepared, of which 3 were from cadaveric donors.<br> It is difficult to predict bleeding volume during lung transplantation due to factors including the degree of adhesion between visceral and parietal pleura. Our analysis suggested that the number of units of blood products required might depend on whether transplantation is single-lung or double-lung, probably indicating that cardiopulmonary bypass usage is a major determinant. Our analysis confirmed that it is important for both transfusion and clinical departments to communicate with each other on a routine basis, and to be prepared to use ABO-mismatched but compatible blood products in order to handle emergency surgery for cadaveric lung transplantation with demand for a large amount of blood products.<br>

    DOI： 10.3925/jjtc.56.606

    CiNii Article

    CiNii Books

    researchmap

    Other Link： http://search.jamas.or.jp/link/ui/2011048595

  • Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases. Reviewed

    Fujii K, Aoyama M, Shinagawa K, Matsuo K, Takenaka K, Ikeda K, Kojima K, Ishimaru F, Kiura K, Ueoka H, Niiya K, Tanimoto M, Harada M

    Int J Hematol   76 ( 2 )   186 - 191   2002.8

    　More details

    Authorship：Lead author   Language：English  

    CiNii Article

    CiNii Books

    researchmap

▼display all

MISC

  • [Manufacturing results of tisagenlecleucel for acute lymphoblastic leukemia: a survey by the CAR-T cell therapy taskforce of the Japan Society of Transfusion Medicine and Cell Therapy].

    Tomoyasu Jo, Tomoko Henzan, Daisuke Tomizawa, Satoru Yoshihara, Kaoru Kahata, Minami Yamada-Fujiwara, Yoshiki Okuyama, Norio Shiba, Keiko Fujii, Yoshihiro Umezawa, Rie Yamazaki, Wataru Takeda, Ryo Hanajiri, Kentaro Fukushima, Naoya Mimura, Junko Ikemoto, Keita Iwaki, Noboru Yonetani, Shin-Ichiro Fujiwara, Masaki Ri, Tokiko Nagamura-Inoue, Ryuji Tanosaki, Yasuyuki Arai

    [Rinsho ketsueki] The Japanese journal of clinical hematology   64 ( 5 )   331 - 337   2023

    　More details

    Language：Japanese  

    The frequency of the manufacturing failure of chimeric antigen receptor (CAR)-T cell therapy in clinical practice is unknown. To clarify the current state of how likely CAR-T cell production is to succeed or fail for B-cell acute lymphoblastic leukemia (B-ALL), we analyzed cases in which the production of tisagenlecleucel was performed for patients with B-ALL at 15 facilities in Japan from October 2019 to March 2022. Total 81 patients (47 males and 34 females) were analyzed. The median age at apheresis was 13 years (1-25) with a median number of prior treatments of 4 (1-9). The numbers of patients with histories of allogeneic transplantation, inotuzumab ozogamicin, or blinatumomab treatments were 51 (63.0%), 26 (32.1%), and 37 (45.7%), respectively. The median blast percentage and CD3+ cell counts in peripheral blood were 0% (0-91.5), and 611/µl (35-4,210) at apheresis, and the median number of CD3+ cells shipped was 2.2×109 (0.5-8.3). While cases with a history of heavy prior treatment before apheresis were included, no manufacturing failures were observed. Continuing to monitor the status of manufacturing failures is necessary as the number of B-ALL cases treated with CAR-T cell therapy increases.

    DOI： 10.11406/rinketsu.64.331

    PubMed

    researchmap

  • Tisagenlecleucelのためのリンパ球採取-末梢血CD3+数と採取効率による処理量決定とロングアフェレーシスでの工夫-

    藤井敬子, 阿部将也, 住居優一, 谷勝真, 浦田知宏, 高木尚江, 閘結稀, 池田亮, 浅野尚美, 小郷博昭, 北村亘, 清家圭介, 大塚文男, 藤井伸治, 藤井敬子, 阿部将也, 住居優一, 谷勝真, 浦田知宏, 高木尚江, 北村亘, 清家圭介, 大塚文男, 藤井伸治

    日本輸血細胞治療学会誌   69 ( 2 )   2023

    　More details

  • Clinical significance of gynecological examinations in LTFU

    鴨井千尋, 鴨井千尋, 藤井伸治, 藤井伸治, 松岡敬典, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   44th   2022

    　More details

  • Development of a new collection procedure for granulocyte apheresis

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 住居優一, 住居優一, 浦田知宏, 浦田知宏, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   44th   2022

    　More details

  • Analysis of cryopreserved unrelated donor bone marrow transplantation under the COVID-19 pandemic

    松村彰文, 藤原英晃, 植田裕子, 守山喬史, 村上裕之, 住井優一, 浦田知宏, 木村真衣子, 近藤匠, 浅田騰, 遠西大輔, 西森久和, 松岡賢市, 藤井敬子, 藤井伸治, 鴨井千尋, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   44th   2022

    　More details

  • Gilteritinib maintenance therapy post-SCT improves the prognosis of patients with R/R FLT3mut AML

    寺尾俊紀, 松岡賢市, 植田裕子, 松村彰文, 松原千哲, 近藤歌穂, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

    　More details

  • Influence of oral microbiota on graft-versus-host disease and its role as a therapeutic target

    神原由依, 藤原英晃, 山本晃, 國廣まり, 大山矩史, 近藤匠, 淺田騰, 遠西大輔, 西森久和, 藤井伸治, 藤井敬子, 松岡賢市, 前田嘉信, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

    　More details

  • Open-label, randomized study to calcium drink for prevention of citrate toxicity of PBSC donor

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 三橋利晴, 住居優一, 住居優一, 谷勝真, 谷勝真, 浦田知宏, 浦田知宏, 木村真衣子, 木村真衣子, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 大塚文男, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

    　More details

  • Modification of post-transplant cyclophosphamide and tacrolimus in haploidentical transplantation

    寺尾俊紀, 松岡賢市, 近藤匠, 高須賀裕樹, 鴨井千尋, 植田裕子, 松村彰文, 松原千哲, 近藤歌穂, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 前田嘉信

    日本造血・免疫細胞療法学会総会プログラム・抄録集   45th   2022

    　More details

  • EBV viremia with NK/T cells as well as B cells after hematopoietic stem cell transplantation

    大山矩史, 西森久和, 村上裕之, 高須賀裕樹, 北村亘, 藤原英晃, 淺田騰, 藤井敬子, 藤井伸治, 遠西大輔, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

    　More details

  • Prognostic impact of Day 30 WT1 after PTCY-haplo in myeloid neoplasm: A multi-center study from OHSG

    北村亘, 藤井伸治, 藤井伸治, 名和由一郎, 杉浦弘幸, 藤下惠悟, 吉岡尚徳, 藤原悠紀, 大山矩史, 村上裕之, 高須賀裕樹, 池内一廣, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 木口亨, 今井利, 平松靖史, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

    　More details

  • Treatment outcome of relapse/refractory DLBCL by tisagenlecleucel

    北村亘, 淺田騰, 藤原英晃, 藤井伸治, 池内一廣, 高須賀裕樹, 大山矩史, 小林宏紀, 福見拓也, 佐伯恭昌, 廻勇輔, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 松村卓郎, 今村豊, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

    　More details

  • A retrospective study of the effects of Defibrotide for VOD/SOS: a single institution experience

    大山矩史, 藤井伸治, 池内一廣, 北村亘, 高須賀裕樹, 鴨井千尋, 淺田騰, 西森久和, 藤井敬子, 藤原英晃, 遠西大輔, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

    　More details

  • Determining processing blood volume due to CD3 cells and adjusting device setting for long apheresis

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 松田真幸, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   43rd   2021

    　More details

  • High-dose steroids within 7 days after diagnosis may improve prognosis of NIPC post HSCT

    神原由依, 藤井伸治, 碓井喜明, 山本晃, 肥後寿夫, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 松岡賢市, 前田嘉信, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

    　More details

  • The effect of live attenuated vaccines after allo-HSCT for adult patients

    鴨井千尋, 鴨井千尋, 吉田将平, 藤井伸治, 藤井伸治, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

    　More details

  • The relationship between steroid usage and the prognosis after CAR-T cell therapy in r/r DLBCL

    北村亘, 淺田騰, 大山矩史, 村上裕之, 高須賀裕樹, 池内一廣, 小林宏紀, 福見拓也, 木村真衣子, 近藤匠, 松田真幸, 池川俊太郎, 池川俊太郎, 今中智子, 藤原悠紀, 浦田真吾, 松村卓郎, 今村豊, 竹内誠, 平松靖史, 近藤英生, 藤原英晃, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 上田恭典, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   83rd   2021

    　More details

  • Efficacy of HLA virtual cross-matched platelet transfusions for platelet transfusion refractoriness in hematopoietic stem cell transplantation (vol 60, pg 473, 2020)

    Keisuke Seike, Nobuharu Fujii, Naomi Asano, Shigenori Ohkuma, Yasushi Hirata, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kazunori Naito, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-ichi Matsuoka, Kazuo Tsubaki, Fumio Otsuka, Yoshinobu Maeda

    TRANSFUSION   60 ( 11 )   2765 - 2765   2020.11

    　More details

    Language：English   Publisher：WILEY  

    DOI： 10.1111/trf.15872

    Web of Science

    researchmap

  • B-ALL performed HLA haploidentical stem cell transplantation using post-transplant cyclophosphamide after administration of inotuzumab ozogemicin

    阿部将也, 藤井伸治, 藤井伸治, 水原健太郎, 浦田知宏, 住居優一, 藤原悠紀, 清家圭介, 三道康永, 中村真, 藤井敬子, 佐伯恭昌, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

    　More details

  • チサゲンレクルユーセル投与後の遷延性血球減少の2症例

    福見拓也, 藤井伸治, 藤井伸治, 神原由依, 池内一廣, 小林宏紀, 木村真衣子, 木村真衣子, 近藤匠, 近藤匠, 松田真幸, 松田真幸, 池川俊太郎, 池川俊太郎, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井敬子, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   82nd   2020

    　More details

  • PTCyは,移植前ニボルマブ治療を受けた患者のTreg恒常性を回復させ,急性GVHDを抑制する

    池川俊太郎, 松岡賢市, 水原健太郎, 福見拓也, 小林宏紀, 住居優一, 近藤匠, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 藤井敬子, 藤井伸治, 藤澤佑香, 今井利, 前田嘉信

    日本血液学会学術集会抄録(Web)   82nd   2020

    　More details

  • 重症侵襲性真菌感染症に対して顆粒球輸注が有効であったB細胞性急性リンパ芽球性白血病の一例

    小林宏紀, 藤井敬子, 藤井敬子, 藤原かおり, 金光喜一郎, 石田悠志, 清家圭介, 清家圭介, 三道康永, 三道康永, 池川俊太郎, 池川俊太郎, 松田真幸, 松田真幸, 近藤匠, 近藤匠, 木村真衣子, 木村真衣子, 高木尚江, 高木尚江, 鷲尾佳奈, 嶋田明, 藤井伸治, 藤井伸治

    日本輸血細胞治療学会誌   66 ( 2 )   2020

    　More details

  • 当院での中枢神経浸潤を有するリンパ腫に対してチオテパを用いた自家移植症例の検討

    小林宏紀, 藤井伸治, 近藤英生, 藤井敬子, 池川俊太郎, 木村真衣子, 近藤匠, 松田真幸, 阿部将也, 池内一廣, 神原由依, 福見拓也, 山本晃, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本血液学会学術集会抄録(Web)   82nd   2020

    　More details

  • Adjusting processed blood volume of apheresis individully based on pre CD34+cell and collection efficiency can be best for both donor and recipient

    藤井敬子, 藤井敬子, 藤井伸治, 藤井伸治, 池川俊太郎, 池川俊太郎, 杉浦弘幸, 杉浦弘幸, 清家圭介, 清家圭介, 三道康永, 三道康永, 廻勇輔, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    日本造血細胞移植学会総会プログラム・抄録集   42nd   2020

    　More details

  • 電子カルテシステムの既存機能を活用した骨髄像診断加算システムの構築と導入効果

    青江伯規, 高橋孝英, 川下隆二, 日野佳弥, 鳥越佳子, 渡邊夏希, 平畑嵐紀, 岡田健, 西森久和, 藤井敬子

    日本臨床検査自動化学会会誌   44 ( 4 )   2019

    　More details

  • アルブミン製剤の輸血部管理による使用目的の把握について

    小郷 博昭, 浅野 尚美, 池田 亮, 閘 結稀, 清家 圭介, 三道 康永, 中村 真, 高木 尚江, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   64 ( 6 )   834 - 835   2018.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 抗Fybに加え新たに抗KANNOを産生した1症例

    池田 亮, 小郷 博昭, 浅野 尚美, 閘 結稀, 清家 圭介, 三道 康永, 中村 真, 高木 尚江, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   64 ( 6 )   829 - 830   2018.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • Efficacy of HLA-Matched PLT Transfusions for Platelet Transfusion Refractoriness in HSCT Patients

    Keisuke Seike, Nobuharu Fujii, Keiko Fujii, Yasuhisa Sando, Makoto Nakamura, Kyosuke Saeki, Yusuke Meguri, Noboru Asada, Daisuke Ennishi, Hisakazu Nishimori, Ken-Ichi Matsuoka, Yoshinobu Maeda

    BLOOD   132   2018.11

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)   Publisher：AMER SOC HEMATOLOGY  

    0

    DOI： 10.1182/blood-2018-99-112365

    Web of Science

    researchmap

  • 造血幹細胞移植における患者指定適合血小板輸血の有効性についての検討(Efficacy of HLA-matched PLT transfusion for platelet transfusion refractoriness in HSCT patients)

    清家 圭介, 藤井 伸治, 藤井 敬子, 三道 康永, 中村 真, 佐伯 恭昌, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 前田 嘉信

    臨床血液   59 ( 9 )   1541 - 1541   2018.9

    　More details

    Language：English   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Yusuke Meguri, Kyosuke Saeki, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION   24 ( 3 )   S326 - S326   2018.3

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)   Publisher：ELSEVIER SCIENCE INC  

    DOI： 10.1016/j.bbmt.2017.12.382

    Web of Science

    researchmap

  • Granulocyte Transfusions for Neutropenic Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation

    Shuntaro Ikegawa, Nobuharu Fujii, Keiko Fujii, Yusuke Meguri, Kyosuke Saeki, Noboru Asada, Hisakazu Nishimori, Ken-ichi Matsuoka, Yoshinobu Maeda

    BLOOD   130   2017.12

    　More details

    Language：English   Publishing type：Research paper, summary (international conference)   Publisher：AMER SOC HEMATOLOGY  

    0

    Web of Science

    researchmap

  • 健常人ドナー末梢血幹細胞採取時のクエン酸中毒発現、電解質異常についての解析

    中村 真, 藤井 敬子, 佐伯 恭昌, 谷 勝真, 黒井 大雅, 高木 尚江, 猪股 知子, 池川 俊太郎, 杉浦 弘幸, 池田 直人, 浅野 豪, 吉田 将平, 西森 久和, 松岡 賢市, 近藤 英生, 前田 嘉信, 藤井 伸治, 谷本 光音

    臨床血液   58 ( 5 )   553 - 553   2017.5

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 生後4カ月以内の乳児における母由来の抗A,抗B抗体検出時の適合血の選択

    浅野尚美, 小郷博昭, 池田亮, 閘結稀, 高木尚江, 山川美和, 吉岡尚徳, 小林優人, 淺田騰, 藤井敬子, 藤井伸治

    日本輸血細胞治療学会誌   63 ( 1 )   3‐8(J‐STAGE)   2017

    　More details

    Language：Japanese  

    DOI： 10.3925/jjtc.63.3

    J-GLOBAL

    researchmap

  • シミュレーションを用いた輸血当直業務トレーニング

    浅野 尚美, 小郷 博昭, 池田 亮, 閘 結稀, 高木 尚江, 中村 真, 谷 勝真, 佐伯 恭昌, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   62 ( 6 )   756 - 757   2016.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 輸血当直における各業務過程の所要時間Turn-around Time(TAT)についての検討

    小郷 博昭, 浅野 尚美, 池田 亮, 閘 結稀, 石川 立則, 吉岡 尚徳, 小林 優人, 高木 尚江, 藤井 敬子, 藤井 伸治, 大塚 文男

    日本輸血細胞治療学会誌   61 ( 6 )   590 - 590   2015.12

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 自家末梢血造血幹細胞移植の前処置において、抗がん剤投与量はBMIに応じて増減すべきか

    谷 勝真, 藤原 英晃, 西森 久和, 松岡 賢市, 藤井 伸治, 近藤 英生, 前田 嘉信, 谷本 光音, 廻 勇輔, 小林 優人, 藤井 敬子

    臨床血液   56 ( 5 )   537 - 537   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 難治性Sweet病を合併したMDSに対して同種造血幹細胞移植を施行した1例

    本倉 恵美, 三道 康永, 佐伯 恭昌, 藤井 伸治, 藤原 英晃, 西森 久和, 松岡 賢市, 近藤 英生, 前田 嘉信, 谷本 光音, 廻 勇輔, 小林 優人, 藤井 敬子, 藤原 暖, 土井 裕子, 加持 達弥, 岩月 啓氏

    臨床血液   56 ( 5 )   538 - 538   2015.5

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 血液疾患患者におけるHLA適合血小板輸血後の有効性評価

    藤井 伸治, 小郷 博昭, 小林 優人, 藤井 敬子, 近藤 英生, 浅野 尚美, 池田 亮, 山川 美和, 高木 尚江, 平田 康司

    日本輸血細胞治療学会誌   61 ( 2 )   258 - 258   2015.4

    　More details

    Language：Japanese   Publisher：(一社)日本輸血・細胞治療学会  

    researchmap

  • 当院における70歳以上の高齢血液疾患患者に対する同種造血幹細胞移植

    近藤 正太郎, 前田 嘉信, 松岡 賢市, 品川 克至, 藤井 敬子, 藤井 伸治, 近藤 英生, 谷本 光音

    日本老年医学会雑誌   51 ( 3 )   293 - 293   2014.5

    　More details

    Language：Japanese   Publisher：(一社)日本老年医学会  

    researchmap

  • DETECTION AND KINETICS OF DONOR-DERIVED ANTI-JRA IN AN UNRELATED BONE MARROW TRANSPLANTATION RECIPIENT: A CASE REPORT

    Ikeda Toru, Ogo Hiroaki, Asano Naomi, Asada Noboru, Fujii Keiko, Fujii Nobuharu

    JJTC   60 ( 3 )   483 - 487   2014

    　More details

    Language：Japanese   Publisher：The Japan Society of Transfusion Medicine and Cell Therapy  

    Jra is a frequently detected red blood cell antigen known as antigen 901005 according to the ISBT nomenclature. The frequency of Jr (a-) is 0.065% among the Japanese population. We herein report a case of a bone marrow transplantation (BMT) recipient in whom donor-derived anti-Jra was detected on day 15 after BMT. The recipient, a male patient in his fifties, had chronic myeloid leukemia in the second chronic phase after a lymphoid blast crisis. He was group A, D+, and Jr (a+) and had no other irregular antibodies. The donor, a female patient in her forties, was group A, D+, Jr (a-) and had anti-Jr (a) antibodies. A total of 6 units of randomly selected red cell concentrate (RCC) was transfused on days 9, 11, and 14 after BMT. The direct globulin test of the recipient was negative before transplantation; however, it changed to positive on day 12 after transplantation. The irregular antibody test result subsequently changed to positive, and anti-Jra was detected on day 15. Based on this result, we used Jr (a-) RCC for the next 16 units of RCC transfusion. Clinically, there were no hemolytic adverse effects. His direct globulin test and irregular antibody test became negative on days 39 and 53, respectively. Although the clinical importance of irregular antibodies in BMT donors remains unclear, establishment of guidelines for blood product selection might be useful when BMT is planned from a donor with irregular antibodies.

    DOI： 10.3925/jjtc.60.483

    CiNii Article

    researchmap

  • 当院同種造血幹細胞移植症例におけるDisease risk indexの有用性の検討

    浅野豪, 近藤英生, 佐伯恭昌, 長谷川詠子, 黒井大雅, 西森久和, 松岡賢市, 浅田騰, 藤井敬子, 藤井伸治, 藤井伸治, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   35th   2013

    　More details

  • 同種移植後のサイトメガロウイルス抗原血症が急性骨髄性白血病の再発に及ぼす影響

    吉田将平, 近藤英生, 浅野豪, 廻勇輔, 吉岡尚徳, 西之原正昭, 藤原英晃, 岡本幸代, 淺田騰, 西森久和, 藤井敬子, 松岡賢市, 藤井伸治, 前田嘉信, 品川克至, 谷本光音

    日本造血細胞移植学会総会プログラム・抄録集   34th   2012

    　More details

  • 細胞療法のための院内細胞採取・処理・保管に関する全国調査

    藤井敬子, 西森久和, 淺田騰, 藤井伸治, 山口麻由美, 池田亮, 浅野尚美, 小郷博昭, 岩月啓氏, 池田和真, 田中朝志, 佐川公矯, 大戸斉, 高橋孝喜

    日本造血細胞移植学会総会プログラム・抄録集   34th   2012

    　More details

  • 中枢神経系悪性リンパ腫に対する自己末梢血幹細胞移植併用大量化学療法

    近藤 英生, 市川 智継, 前田 嘉信, 黒川 和彦, 青山 一利, 吉田 将平, 原 嘉孝, 新谷 大悟, 西森 久和, 藤井 敬子, 藤井 伸治, 品川 克至, 谷本 光音

    臨床血液   52 ( 9 )   1127 - 1127   2011.9

    　More details

    Language：Japanese   Publisher：(一社)日本血液学会-東京事務局  

    researchmap

  • 中枢神経系悪性リンパ腫に対する自己末梢血幹細胞移植併用大量化学療法

    近藤 英生, 前田 嘉信, 青山 一利, 吉田 将平, 原 嘉孝, 廻 勇輔, 新谷 大悟, 品川 克至, 西森 久和, 藤井 敬子, 藤井 伸治, 黒住 和彦, 市川 智継, 谷本 光音

    日本リンパ網内系学会会誌   51   98 - 98   2011.6

    　More details

    Language：Japanese   Publisher：(一社)日本リンパ網内系学会  

    researchmap

  • 同種末梢血幹細胞採取における至適タイミングの検討

    藤井敬子, 藤井敬子, 西森久和, 西森久和, 藤井伸治, 藤井伸治, 池田和真, 谷本光音, 谷本光音

    臨床血液   52 ( 9 )   2011

    　More details

  • 貯血式自己血採血における血管迷走神経反射の検討

    西森久和, 藤井敬子, 遠藤麻里子, 池田亮, 浅野尚美, 小郷博昭, 池田和真, 小出典男

    日本輸血細胞治療学会誌   57 ( 2 )   2011

    　More details

  • 当院での貯血式自己血採血における血管迷走神経反射の検討

    西森久和, 藤井敬子, 遠藤麻里子, 池田亮, 浅野尚美, 小郷博昭, 池田和眞, 小出典男

    日本輸血細胞治療学会誌   57 ( 1 )   2011

    　More details

  • 当院での緊急時O型赤血球輸血の現状

    小郷博昭, 池田亮, 浅野尚美, 遠藤麻里子, 西森久和, 藤井敬子, 池田和真, 小出典男

    日本輸血細胞治療学会誌   57 ( 1 )   2011

    　More details

  • 同種末梢血幹細胞採取における至適タイミングの検討

    藤井敬子, 池田亮, 浅野尚美, 小郷博昭, 西森久和, 小出典男, 池田和真

    日本輸血細胞治療学会誌   57 ( 2 )   2011

    　More details

  • 輸血に関するインシデントの検討

    浅野尚美, 池田亮, 小郷博昭, 西森久和, 藤井敬子, 池田和真, 小出典男

    日本輸血細胞治療学会誌   57 ( 2 )   2011

    　More details

  • 輸血検査の検体間違いに関するインシデントの検討

    浅野尚美, 池田亮, 小郷博昭, 山口麻由美, 西森久和, 藤井敬子, 藤井伸治, 池田和眞, 岩月啓氏

    日本輸血細胞治療学会誌   57 ( 6 )   2011

    　More details

  • 日本輸血・細胞治療学会による細胞療法の体制に関する全国調査

    藤井敬子, 西森久和, 藤井伸治, 池田亮, 浅野尚美, 小郷博昭, 岩月啓氏, 池田和眞, 田中朝志, 佐川公矯, 大戸斉, 高橋孝喜

    日本輸血細胞治療学会誌   57 ( 6 )   2011

    　More details

  • 細胞療法のための細胞採取・処理・保管に関するアンケート調査

    藤井敬子, 西森久和, 池田和真, 遠藤麻里子, 池田亮, 浅野尚美, 小郷博昭, 小出典男, 田中朝志, 佐川公矯, 高橋孝喜, 大戸斉

    日本造血細胞移植学会総会プログラム・抄録集   33rd   2011

    　More details

▼display all

Presentations

  • 顆粒球アフェレーシス―中分子HES（ボルベン®）で上手く採るには？― Invited

    藤井敬子

    第43回日本アフェレシス学会学術大会  2022.11.12 

    　More details

    Event date： 2022.11.11 - 2022.11.12

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

    researchmap

  • キムリア原材料採取としてのTNC採取と採取効率

    藤井敬子

    第28回日本輸血・細胞治療学会秋季シンポジウム  2021.10.9 

    　More details

    Event date： 2021.10.8 - 2021.10.9

    Language：Japanese   Presentation type：Symposium, workshop panel (nominated)  

    researchmap

  • 造血幹細胞移植のための同種骨髄液の凍結保存について

    藤井敬子

    骨髄バンク中四国ブロック会議共催中四国ブロックセミナー  2021.2.20 

    　More details

    Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • Open-label, randomized study to calcium drink for prevention of citrate toxicity of PBSC donor

    2023.2.10 

    　More details

    Event date： 2023.2.10 - 2023.2.12

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • ロングアフェレーシスを行った同種末梢血幹細胞採取の有効性と安全性について

    藤井敬子, 住居優一, 浦田知宏, 木村真衣子, 近藤匠, 髙木尚江, 閘, 結稀, 池田亮, 浅野尚美, 小郷博昭, 大塚文男, 藤井伸治

    第70回日本輸血・細胞治療学会学術総会  2022.5.29 

    　More details

    Event date： 2022.5.27 - 2022.5.29

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • 当院におけるSpectra Optia 60例の顆粒球アフェレーシス—新規採取手順の開発にむけて—

    藤井敬子, 藤井伸治, 住居優一, 浦田知宏, 木村真衣子, 近藤匠, 藤原英晃, 淺田騰, 遠西大輔, 西森久和, 松岡賢市, 前田嘉信

    第44回日本造血・免疫細胞療法学会総会  2022.5.14 

    　More details

    Event date： 2022.5.12 - 2022.5.14

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • 骨髄濃縮を行った骨髄移植72症例の後方視的検討―赤血球除去の有用性、骨髄凍結の安全性を含めて―

    藤井敬子, 木村真衣子, 近藤 匠, 松田真幸, 高橋孝英, 高木尚江, 閘 結稀, 池田 亮, 浅野尚美, 小郷博昭, 前田嘉信, 大塚文男, 藤井伸治

    第69回日本輸血・細胞治療学会学術総会  2021.6.6 

    　More details

    Event date： 2021.6.4 - 2021.6.6

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • Determining processing blood volume due to CD3 cells and adjusting device setting for long apheresis

    2021 

    　More details

    Event date： 2021.3.5 - 2021.3.7

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • 末梢血幹細胞採取ドナーの負担軽減を目指した処理血液量減量の試み 第42回日本造血細胞移植学会総会

    藤井 敬子, 藤井 伸治, 池川 俊太郎, 杉浦 弘幸, 清家 圭介, 三道 康永, 廻 勇輔, 淺田 騰, 遠西 大輔, 西森 久和, 松岡 賢市, 前田 嘉信, 池川 俊太郎, 杉浦 弘幸, 清家 圭介, 三道 康永

    第42回日本造血細胞移植学会総会  2020.3 

    　More details

    Event date： 2020.3

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • CD34陽性細胞回収率の違いからみた処理血液量決定―末梢血幹細胞採取を効率よく終わらせるために―

    藤井敬子, 糸島浩一, 岡田 健, 小川弘子, 草野展周, 大塚文男

    第66回日本臨床検査医学会学術集会  2019.11.22 

    　More details

    Event date： 2019.11.21 - 2019.11.24

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • 自家と同種におけるCD34陽性細胞回収率の違いからみた処理量決定 －末梢血幹細胞採取を効率よく終わらせるために－

    藤井敬子, 藤井伸治, 清家圭介, 三道 康永, 中村 真, 閘 結稀, 池田 亮, 浅野 尚美, 小郷 博昭, 髙木尚江, 大塚文男

    第67回日本輸血・細胞治療学会学術総会  2019.5.24 

    　More details

    Event date： 2019.5.23 - 2019.5.25

    Language：Japanese   Presentation type：Oral presentation (general)  

    researchmap

  • CAR-T治療の運用の実際と紹介時のポイント

    藤井敬子

    中四国エリアKYMRIAH Network Live Discussion  2021.9.10 

    　More details

    Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • CAR-T Apheresis Collection Seminar

    CAR-T Apheresis Collection Seminar  2021.6.28 

    　More details

    Language：Japanese   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • CAR-T細胞療法のための白血球アフェレーシス ―同種リンパ球輸注と比較して―

    藤井敬子, 木村真衣子, 小林宏紀, 近藤 匠, 松田真幸, 池川俊太郎, 清家圭介, 三道康永, 髙木尚江, 閘 結稀, 池田 亮, 浅野尚美, 小郷博昭, 藤井伸治, CAR-T細胞療法のための白血球アフェレーシス

    第68回日本輸血・細胞治療学会学術総会  2020.5 

    　More details

    Language：Japanese  

    researchmap

▼display all

Research Projects

  • 急性移植片対宿主病の重篤化抑制を目的としたテプレノン併用免疫抑制療法の開発

    Grant number：21K12751  2021.04 - 2024.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)  Grant-in-Aid for Scientific Research (C)

    藤井 敬子

    　 More details

    Grant amount：\4160000 （ Direct expense: \3200000 、 Indirect expense：\960000 ）

    特定臨床研究「重症急性移植片対宿主病の発症抑制を目的としたテプレノン併用免疫抑制療法の開発」として立案し、認定臨床研究審査委員会に審査を依頼し承認を得た（1月17日）。jRCT公表（1月27日）、臨床研究保険加入の完了を待って、令和４年2月26日から実施となった。第1例目の症例の登録が令和4年3月1日にあり、以降3月末までに4例の登録があった。研究は現在リクルート中である。
    研究計画立案にあたって、ARO支援で統計解析コンサルタントを依頼した。審査に当たって、各種申請書類の準備をおこなった。審査後の厚生労働大臣（地方厚生局）へ報告の手続き、臨床研究開始に当たって臨床研究保険への加入、モニタリング実施を行った。
    本研究の概要は、当施設の血液・腫瘍内科で行うほぼ全ての移植症例において、同意取得の後テプレノン投与群、非投与群にランダム化割付けを行って、急性移植片対宿主病（aGVHD）の重症例（Grade III以上）の発症率について比較を行う。このほか、移植後100日目の生存率、GVHD重篤化の早期予測を可能とする因子の探索、テプレノンによるTrx-1、HSP-70、酸化ストレスマーカー、サイトカインの発現変化を評価する。介入は、前処置開始日より3週間、テプレノンを服用する（通常のGVHD予防は行う）。採血は移植後4週間までに4回のタイミングで行ってバイオバンクに集積し、血清・血漿に分けて保管する。80症例について症例報告書からデータの集積を行って、バイオマーカーの探索的測定や重症GVHD発症との関連性などについて統計学的解析を行って学会発表・論文化を予定する。

    researchmap